131I联合泼尼松龙片对Graves病患者骨代谢及TRAb、A-TPO水平的影响

Abstract
Figure/Table
References (15)
Related Citation (2)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the influence of131I combined with Prednisolone Tablets on bone metabolism and anti-Thyroid-Peroxidase antibody(A-TPO)and thyrotropin receptor antibody(TRAb)levels among patients with Graves disease.Methods89 patients with Graves disease treated in our hospital from September 2014 to December 2016 were selected and randomly divided into the control group(45 cases)and the observation group(44 cases).The control group was treated with131I alone,and the observation group was given orally administrated with131I combined with Prednisolone Tablets.The clinical efficacy was compared between the two groups.ResultsThe level of aminoterminal propeptide of typeⅠprocollagen (PINP),TRAb and A-TPO in the two groups after treatment was lower than that before treatment,PTH in the two groups after treatment was higher than that before treatment,with significant difference(P＜0.05).The level of PINP,TRAb and A-TPO of the observation group after treatment was lower than that of the control group,the level of PTH of the observation group after treatment was higher than that of the control group,with significant difference(P＜0.05).The total amount of Bisoprolol Tablets and Thiamazole Tablets of the observation group was lower than that of the control group,the recovery time of thyroid function of the observation group was shorter than that of the control group,with significant difference(P＜0.05).ConclusionThe effect of131I combined with Prednisolone Tablet in the treatment of Graves disease is significant,and which can better improve bone metabolism and A-TPO and TRAb levels.Therefore,it is worth promoting.

Key words： 131I Prednisone Tablets Graves disease Bone metabolism

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHONG Bin-li

Cite this article:

ZHONG Bin-li. Influence of131I combined with Prednisolone Tablets on bone metabolism and A-TPO and TRAb levels among patients with Graves disease[J]. 中国当代医药, 2017, 24(23): 8-10.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I23/8

[1]	马文杰，易茜璐，于明香.甲状腺与骨质疏松关系的研究进展[J].复旦学报（医学版），2012，39（4）：5-9.
[2]	孟召伟，谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志，2011，35（4）：193-201．
[3]	Nwatsock JF，Taieb D，Essonnier L，et al.Radioiodine thyroid ablation in graves hyperthyroidism：merits and pitfalls[J].World J Nucl Med，2012，11（1）：7-11．
[4]	王锋.免疫抑制剂联合甲巯咪唑对Graves病患者血清炎性因子及A-TPO、TRAb水平的影响[J].现代中西医结合杂志，2016，25（35）：3912-3914.
[5]	张琰，何煜，龚俊，等.Graves病肝损害与甲状腺功能及免疫因素的关系[J].中国医药导报，2015，12（34）：56-59.
[6]	金进.泼尼松联合甲巯咪唑与单纯口服甲巯咪唑治疗Graves病疗效比较[J].蚌埠医学院学报，2012，37（6）：699-701．
[7]	马文杰，吕朝阳，张尧.住院Graves病患者骨代谢状况与131I治疗后转归分析[J].复旦学报（医学版），2017，44（2）：186-188.
[8]	姚龙江，韩玉清，丁福万，等.血清TRAb水平在Graves病诊治中的重新评价[J].中国免疫学杂志，2013，29（11）：1190-1192.
[9]	苑姗姗，于楠，高莹，等.Graves病、Graves病合并桥本甲状腺炎及桥本甲状腺毒症患者血清中TgAb及TPOAb IgG 亚型的分布及意义[J].中华医学杂志，2014，94（2）：110-114.
[10]	张海三，张红星，刘保平，等.Graves病患者131I治疗后疾病影响程度与生活质量变化[J].中华行为医学与脑科学杂志，2014，23（10）：904-908.
[11]	蒋学超，储以微.B细胞在Graves病中的作用[J].国际免疫学杂志，2014，37（5）：367-370.
[12]	马学芹，于世鹏.初发Graves病患者131I治疗前后IL-23/Th17轴相关因子水平的变化及意义[J].中国免疫学杂志，2013，29（7）：733-735.
[13]	罗顺葵，谢丹红.Graves病研究新进展[J].新医学，2014，41（3）：202-205．
[14]	吴立兵，刘刚，万华兵.女性Graves病患者行131I治疗前后骨密度及血清骨代谢指标变化的研究分析[J].标记免疫分析与临床，2015，22（10）：1019-1021.
[15]	王超群，陈鸿颜，严娟娟.131I联合泼尼松龙片治疗Graves病的疗效分析[J].标记免疫分析与临床，2014，21（1）：33-35.